Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5172 - Predictors of Survival in Patients with Incurable Cancer


28 Sep 2019


Poster Display session 1


Supportive Care and Symptom Management

Tumour Site


Erin Stella Sullivan


Annals of Oncology (2019) 30 (suppl_5): v718-v746. 10.1093/annonc/mdz265


E.S. Sullivan1, L.E. Daly1, R. Dolan2, É.B. Ní Bhuachalla1, M. Fallon3, C. Simmons3, D.C. McMillan2, B. Laird3, A.M. Ryan1, D.G. Power4

Author affiliations

  • 1 School Of Nutritional Sciences, University College Cork, T12 K8AF - Cork/IE
  • 2 Academic Unit Of Surgery, University of Glasgow, Glasgow/GB
  • 3 Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh/GB
  • 4 Departments Of Medical Oncology, Cork & Mercy University Hospitals, T12 K8AF - Cork/IE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5172


The aim of the present study was to investigate predictors of survival in a cohort of patients with incurable cancer. This may highlight areas of care which can be addressed to optimise outcomes.


Patient demographics, performance status (ECOG), inflammatory markers (modified Glasgow Performance Score (mGPS)), and nutritional parameters [BMI, % weight loss (WL)] were recorded. Baseline body composition were examined using computed tomography (CT) images. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cancer cachexia (CC) was defined using the consensus definition (2011). Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates – age, sex & site.


In total, 1027 patients were recruited (51% male, median age 66 years). Gastrointestinal cancer was most common (40%) and metastatic disease was present in 87% of patients. In total, 86% were on active chemotherapy treatment. On multivariate analysis, primary site, ECOG-PS, WL and mGPS predicted survival. Lung and GI cancer patients had higher risk of death compared to other tumour groups [HR:1.769 (95% CI:1.305–2.398), p < 0.001 and HR:1.576 (95% CI:1.211–2.053), p = 0.001, respectively]. mGPS score of 1 or 2 were associated with increased risk of death versus mGPS of 0 [HR:1.399 (95% CI:1.024–1.910), p = 0.035 & HR:1.831 (95% CI:1.442–2.324), p < 0.001, respectively]. WL > 10% in the preceding 3 months was associated with reduced survival [HR:2.501 (95% CI:1.425–4.389), p = 0.001]. Sarcopenia, CC and low MA were significant predictors of survival on univariate analysis, but not on multivariate analysis.


Independent predictors of survival in this cohort of advanced cancer patients were cancer site, ECOG, WL > 10% and mGPS, the latter two being important components of the cancer cachexia syndrome. Attenuation of weight loss and inflammation may improve outcomes for patients undergoing palliative treatment for cancer.

Clinical trial identification

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.